Otoimmün Epilepsi

Canpolat M, Kumandas S, Poyrazoglu HG, Gumus H, Elmali F, Per H. Prevalence and risk factors of epilepsy among school children in Kayseri City Center, an urban area in Central Anatolia, Turkey. Seizure 2014;23(9):708-16.

Steriade C, Britton J, Dale RC, Gadoth A, Irani SR, Linnoila J, McKeon A, Shao XQ, Venegas V, Bien CG. Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune-associated epilepsy: Conceptual definitions. Epilepsia. 2020 Jul;61(7):1341-1351.

Greco A, Rizzo MI, De Virgilio A, Conte M, Gallo A, Attanasio G, et all. Autoimmune epilepsy. Autoimmun Rev. 2016;15(3):221-5.

Flammer J, Neziraj T, Rüegg S, Pröbstel AK. Immune Mechanisms in Epileptogenesis: Update on Diagnosis and Treatment of Autoimmune Epilepsy Syndromes. Drugs. 2023 Feb;83(2):135-158.

Bektaş Ö, Jacobson L, Tutkak H, Karagöl S, Lang B, Clover L, Vincent A, et al. Epilepsy and autoimmunity in pediatric patients. Neuropediatrics. 2015;46(1):13-9.

Suleiman J, Dale RC. The recognition and treatment of autoimmune epilepsy in children. Dev Med Child Neurol. 2015;57(5):431-40.

Hacohen YM, Singh RM, Forsyth VM, Absoud MMP, Lim MMP. CSF albumin and immunoglobulin analysesin childhood neurologic disorders. Neurol Neuroimmunol Neuroinflamm 2014; 1: e10

Dhamija R, Renaud DL, Pittock SJ, McKeon A, Lachance DH, Nickels KC, et al. Neuronal voltage-gated potassium channel complex autoimmunity in children. Pediatr Neurol 2011;44(4):275-81..

Haberlandt E, Bast T, Ebner A, Holthausen H, Kluger G, Kravljanac R, Kröll-Seger J, et al. Limbic encephalitis in children and adolescents. Arch Dis Child. 2011; 96(2): 186-91.

Moscato EH, Peng X, Jain A, Parsons TD, Dalmau J, Balice-Gordon RJ. Acute mechanisms underlying antibody effects in anti-N-methyl-D-aspartate receptor encephalitis. Ann Neurol 2014; 76: 108–19.

Schmitt SE, Pargeon K, Frechette ES, Hirsch LJ, Dalmau J, Friedman D. Extreme delta brush A unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology 2012; 79: 1094–100.

Gitiaux C, Simonnet H, Eisermann M, Leunen D, Dulac O, Nabbout R,et al. Early electro-clinical features may contribute to diagnosis of the anti-NMDA receptor encephalitis in children. Clin Neurophysiol 2013; 124(12):2354-61.

Dubey D, Pittock SJ, McKeon A. Antibody Prevalence in Epilepsy and Encephalopathy score: Increased specificity and applicability. Epilepsia. 2019 Feb;60(2):367-369. De

Bruijn MAAM, Bastiaansen AEM, Mojzisova H, et al. Antibodies Contributing to Focal Epilepsy Signs and Symptoms Score. Ann Neurol. 2021 Apr;89(4):698-710. doi: 10.1002/ana.26013. Epub 2021 Jan 27.

Graus F, Saiz A, Dalmau J. Antibodies and neuronal autoimmune disorders of the CNS. J Neurol 2010; 257(4): 509-17.

Errichiello L, Striano S, Zara F, Striano P. Temporal lobe epilepsy and anti glutamic acid decarboxylase autoimmunity. Neurol Sci 2011; 32: 547-50.

Saiz A, Blanco Y, Sabater L, González F, Bataller L, Casamitjana R, Ramió-Torrentà L, Graus F. Spectrum of neurological syndromes associated with glutamic acid decarboxylase antibodies: diagnostic clues for this association. Brain. 2008;131: 2553-63.

Falip M, Carreño M, Miró J, Saiz A, Villanueva V, et al. Prevalence and immunological spectrum of temporal lobe epilepsy with glutamic acid decarboxylase antibodies. Eur J Neurol. 2012; 19(6):827-33.

Malter MP, Helmstaedter C, Urbach H, Vincent A, Bien CG. Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol 2010; 67(4): 470-8

Errichiello L, Perruolo G, Pascarella A, Formisano P, Minetti C, Striano S,et al. Autoantibodies to glutamic acid decarboxylase (GAD) in focal and generalized epilepsy: A study on 233 patients. J Neuroimmunol. 2009;211(1-2):120-3.

Smith KM, Zalewski NL, Budhram A, Britton JW, So E, Cascino GD, Ritaccio AL, McKeon A, Pittock SJ, Dubey D. Musicogenic epilepsy: Expanding the spectrum of glutamic acid decarboxylase 65 neurological autoimmunity. Epilepsia. 2021 May;62(5):e76-e81.

Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008;7:1091-8.

Vincent A, Irani SR, Lang B. The growing recognition of immunotherapy-responsive seizure disorders with autoantibodies to specific neuronal proteins. Curr Opin Neurol 2010; 23: 144e50

Bektaş Ö, Tanyel T, Kocabaş BA, Fitöz S, Ince E, Deda G. Anti-N-methyl-D-aspartate receptor encephalitis that developed after herpes encephalitis: a case report and literature review. Neuropediatrics 2014;45(6):396-401.

Lin N, Liu Q, Chen J, Jin L, Huang Y, Lu Q, Guan H. Long-term seizure outcomes in patients with anti-Leucine-rich glioma-inactivated 1 encephalitis. Epilepsy Behav. 2021 Sep;122:108159.

Irani SR, Alexander S, Waters P, Kleopa KA, Pettingill P, Zuliani L, Peles E, Buckley C, Lang B, Vincent A. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain. 2010 Sep;133(9):2734-48.

van Sonderen A, Thijs RD, Coenders EC, Jiskoot LC, Sanchez E, de Bruijn MA, van Coevorden-Hameete MH, Wirtz PW, Schreurs MW, Sillevis Smitt PA, Titulaer MJ. Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up. Neurology. 2016 Oct 4;87(14):1449-1456.

Petit-Pedrol M, Armangue T, Peng X, Bataller L, Cellucci T, Davis R,et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol 2014; 13: 276–86.

Boronat A, Sabater L, Saiz A, Dalmau J, Graus F. GABAB receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology 2011; 76: 795–800.

Lancaster E, Lai M, Peng X, Hughes E, Constantinescu R, Raizer J,, et al. Antibodies to the GABAB receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 2010; 9: 67–76.

Gozzard P, Maddison P. Which antibody and which cancer in which paraneoplastic syndromes? Pract Neurol 2010; 10(5): 260-70.

Schiess N, Pardo CA. Hashimoto's encephalopathy. Ann N Y Acad Sci 2008;1142:254-65

Falip M, Carreño M, Miró J, Saiz A, Villanueva V, Quílez A, et al. Prevalence and immunological spectrum of temporal lobe epilepsy with glutamic acid decarboxylase antibodies. Eur J Neurol 2012; 19(6): 827-33.

Peschen-Rosin R, Schabet M, Dichgans J. Manifestation of Hashimoto's encephalopathy years before onset of thyroid disease. Eur Neurol 1999;41(2):79-84.

Bektas Ö, Yılmaz A, Kendirli T, Sıklar Z, Deda G. Hashimoto encephalopathy causing drug-resistant status epilepticus treated with plasmapheresis. Pediatr Neurol 2012; 46(2): 132-5.

Mackworth-Young CG, Hughes GR. Epilepsy: an early symptom of systemic lupus erythematosus. J Neurol Neurosurg Psychiatry 1985; 48(2): 185.

Pardo A, González-Porque P, Gobernado JM, Jiménez-Escrig A, Lousa M. Study of antiphospholipid antibodies in patients treated with antiepileptic drugs. Neurologia 2001; 16(1): 7-10.

Verrot D, San-Marco M, Dravet C, Genton P, Disdier P, Bolla G, et al. Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy. Am J Med 1997; 103(1): 33-7.

Eriksson K, Peltola J, Keränen T, Haapala AM, Koivikko M. High prevalence of antiphospholipid antibodies in children with epilepsy: a controlled study of 50 cases. Epilepsy Res 20014; 6(2): 129-37.

Cimaz R, Romeo A, Scarano A, Avcin T, Viri M, Veggiotti P, et al. Prevalence of anti cardiolipin, anti-beta2 glycoprotein I, and anti-prothrombin antibodies in young patients with epilepsy. Epilepsia 2002; 43: 52-9.

Husari KS, Dubey D. Autoimmune Epilepsy. Neurotherapeutics. 2019 Jul;16(3):685-702.